DOCSLIB.ORG

Controversies in Multiple Myeloma Outline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Controversies in Multiple Myeloma Outline Controversies in Multiple Myeloma Outline • Myeloma: Introduction • Relapsed refractory case • Definition of relapsed/refractory • When to treat • Why treatment • The Who, When, and Why of Treatment • https://www.ashclinicalnews.org/features/controversies-myeloma- treatment/ Multiple Myeloma • Median age at diagnosis: 69 yrs • 5-yr survival has improved substantially (43% in 2002- 2008 vs 28% in 1987-1989) due to novel agents • Sensitive to treatment, but not curable • Progression inevitable Multiple Myeloma • Median age at diagnosis: 69 yrs • 5-yr survival has improved substantially (43% in 2002- 2008 vs 28% in 1987-1989) due to novel agents • Sensitive to treatment, but not curable • Progression inevitable • Goal of treatment: induce a long-term, disease-free survival with normal quality of life • For a long-term, disease-free survival depth of response is important Natural History of Multiple Myeloma Asymptomatic Symptomatic 100 ACTIVE 2. RELAPSE MYELOMA REFRACTORY 50 1. RELAPSE RELAPSE MGUS or M Protein (g/L) M Protein smoldering myeloma Plateau 20 remission First-line Rx Second-line Rx Third-line Rx Newly Dx15,000/year in US 45,000/year in US IMWG Criteria for Diagnosis of Multiple Myeloma MGUS Smoldering Myeloma Multiple Myeloma § M protein < 3 g/dL § M protein ≥ 3 g/dL § Clonal BM plasma cell > § Clonal plasma cells in BM (serum) or ≥ 500 mg/24 10% or Extramedullary < 10% hrs (urine) plasmacytoma § No myeloma defining § Clonal plasma cells in § AND 1 or more events BM ≥ 10% to 60% myeloma defining § No myeloma defining events events § ≥ 1 CRAB* or § SLiM feature *C: Calcium elevation (> 11 mg/dL or > 1 mg/dL higher than ULN) R: Renal insufficiency (creatinine clearance < 40 mL/min or serum creatinine > 2 mg/dL) A: Anemia (Hb < 10 g/dL or 2 g/dL < normal) B: Bone disease (≥ 1 lytic lesions on skeletal radiography, CT, or PET-CT) § SLiM: Sixty percent of plasma cells in BM; Serum free Liight chain ratio ≥ 100; > 1 MRI focal lesion (>5 mm each) § MDE Rajkumar SV, et al. Lancet Oncol. 2014;15:e538-e548. Smoldering Multiple Myeloma 100 Smoldering MM MGUS 80 27% will convert in 15 years 78 Roughly 2% 73per year 66 60 27% more will convert in remaining 15 yrs 51 ~ 2% per yr 40 51% will convert in first 5 yrs ~ 10% per yr 20 21 Probability of Progression (%) 16 4 10 0 0 5 10 15 20 25 Yrs Since Diagnosis Kyle RA, et al. N Engl J Med. 2007;356:2582-2590. Greipp PR, et al. J Clin Oncol. 2005;23:3412-3420. For SMM Smoldering Myeloma 2014 • The Mayo Clinic model (2007-2008) uses • M-protein (≥3 g/dL), § M protein ≥ 3 g/dL (serum) or ≥ 500 mg/24 • BMPC% (≥10%), hrs (urine) • and the ratio oF involved to uninvolved serum Free light chains (FLCr) § Clonal plasma cells in (≥8) BM ≥ 10% to 60% • categorize patients into three risk categories, with a 76% risk oF § No myeloma defining events progression in 5 years among those with all three oF the above characteristics. • The Spanish model uses • the proportion oF BMPCs with aberrant PC phenotype on Flow cytometry (≥95%) and reduction in uninvolved immunoglobulins (immunoparesis) to identify high-risk patients. • Abnormalities detected on imaging oF spine or whole body using magnetic resonance imaging (MRI), and underlying cytogenetic abnormalities also guide clinicians in identifying high-risk patients. Blood Cancer Journal (2018)8:59. For SMM New risk classification will (possible) be available Smoldering Myeloma • Arjun Lakshman1, S. Vincent Rajkumar1, Francis K. Buadi1, et al. § M protein ≥ 3 g/dL (serum) or ≥ 500 mg/24 reported in Blood Cancer Journal (2018)8:59. hrs (urine) § Clonal plasma cells in BM ≥ 10% to 60% 0 § No myeloma defining 1 events >2 1 2 BMPC% > 20%, 3 M-protein > 2 g/dL, and FLC ratio > 20 at diagnosis M-protein (≥3 g/dL), BMPC% (≥10%), and the ratio of involved to uninvolved serum free light chains (FLCr) (≥8) • Arjun Lakshman1, S. Vincent Rajkumar1, Francis K. Buadi1, et al. For SMM reported in Blood Cancer Journal (2018)8:59. Smoldering Myeloma § M protein ≥ 3 g/dL (serum) or ≥ 500 mg/24 hrs (urine) § Clonal plasma cells in BM ≥ 10% to 60% § No myeloma defining events BMPC% > 20%, 0 M-protein > 2 g/dL, 1 and FLC ratio > 20 at diagnosis >2 92 (47.8%) BMPC% > 10%, 1 M-protein > 3 g/dL, 2 and FLC ratio > 8 at diagnosis 3 For SMM New risk classification will be available Smoldering Myeloma • Arjun Lakshman1, S. Vincent Rajkumar1, Francis K. Buadi1, et al. reported in Blood Cancer Journal (2018)8:59. § M protein ≥ 3 g/dL (serum) or ≥ 500 mg/24 hrs (urine) § Clonal plasma cells in BM ≥ 10% to 60% § No myeloma defining events 0 1 1 2 >2 3 BMPC% > 20%, M-protein > 2 g/dL, and FLC ratio > 20 at diagnosis can be used to risk stratify patients with SMM. Case 62 years-old female, ECOG 1-2 without other comorbidity • Diagnosed of MM since 2006 (2549) (12 years ago)(52yo) • VAD was given 6 cycles, CR after 3rd cycle • Evaluate by BM, SPEP, IFE • Bisphosphonate was given every cycle of treatMent and after reMission every 3 Mo. for 2 years, then every year Vincristine Doxorubicin DexaMethasone Symptomatic Multiple Myeloma: Frontline Therapy Initial Approach to Treatment of Myeloma Nontransplant Candidate Transplant (based on age, performance Candidate status, and comorbidities) Induction treatment Induction treatment (4-6 cycles) Maintenance Stem cell harvest Stem cell transplantation Consolidation therapy? Maintenance ASCT: Eligibility Despite novel agents, ASCT remains a standard component of MM treatment Candidates Treatments • Eligibility can depend on • NCCN Category 1 transplant center • VD, VTD, PAD (Bor/doxo/dexa) • Factors/considerations: • Lenalidomide/dexamethasone (RD) • Age • NCCN Category 2A • Cytogenetic abnormalities • CyBorD • Disease status/stage • Bor/len/dex (VRD) • Type of frontline therapy and response • Carfil/len/dex (CRd) • Organ function Phase III Trials: Novel Agent Induction for Transplant-Eligible Patients Trial Regimens n ≥ VGPR, % Median OS, % PFS, After Induction After First ASCT Mos [1] Harousseau VD 240 38 P < .001 54 P < .001 36 3 yr: 81 VAD 242 15 37 30 3 yr: 77 [2] Cavo VTD 413 62 P < .001 79 P < .001 3 yr: 68% 3 yr: 86 VAD 414 28 58 3 yr: 56% 3 yr: 84 [3] Sonneveld PAD 413 42 P < .001 76 P < .001 35 5 yr: 61 VAD 414 14 56 8 5 yr: 55 Rosiñol[4] VTD 130 60 56 4 yr: 74 TD 127 29 NR 28 4 yr: 65 VMBCP/ 129 36 36 4 yr: 70 VBAD/B Moreau[5] VTD 100 49 74 26 P = .05 P = .02 NR VD 99 36 58 30 RaJKumar[6] RD 223 42 50 3 yr: 92 P < .001 P = .04 NR Rd 222 24 40 NR 1. Harousseau JL, et al. J Clin Oncol. 2006;24:431-436. 2. Cavo M, et al. Lancet. 2010;376;2075-2085. 3. Sonneveld P, et al. J Clin Oncol. 2012;30:2946-2955. 4. Rosiñol L, et al. Blood. 2012;120:1589-1596. 5. Moreau P, et al. Blood. 2011;118:5752-5758. 6. Rajkumar SV, et al. Lancet Oncol. 2010;11:29-37. MM Induction in Transplant-ineligible MM Patients: Triplets vs Doublets • Some comparative efficacy data available[1] • VTD superior to TD, – MPT superior to MP including in pts with t(4;14)[2] – VMP superior to MP • VTD superior to VD • CyBorD similar to VTD – MPR superior to MP • Triplet vs doublet still subject to some debate, due in part to lack of randomized data • Appropriate use of doublet therapy? • Ineligibility issues, especially in the elderly • Transplant eligibility affects choice of regimen 1. Rajkumar SV. ASH Education Book. 2012;1:354-361. 2. Cavo M, Et al. Lancet. 2010;376:2075-2085. 62 years-old female, ECOG 1-2 without other comorbidity • Diagnosed of MM since 2006 (2549) (12 years ago)(52yo) • VAD was given 6 cycles, CR after 3rd cycle • Evaluate by BM, SPEP, IFE • Bisphosphonate was given every cycle of treatMent and after reMission every 3 Mo. for 2 years, then every year • Five years later (7 years ago), she developed More aneMia, bone pain and increase plasma cell in BM in 2011 (2554) When to treat R/R myeloma? • Symptomatic relapse • Asymptomatic relapse • CRAB symptoms • Significant paraprotein relapse • New extramedullary • Doubling of the paraprotein in 2 plasmacytoma months • High-risk disease • Aggressive disease at diagnosis • Renal failure • Extramedullary plasmacytoma • High LDH • Light chain escape/non- secretory MM Laubach, et al. IMWG recommendation for RRMM. Leukemia. 2015 Dec 29. [Epub ahead of print] Dimopoulos, et al. Cancer Treatment Reviews. 2015; 41: 827–835 Factors should be considered in R&R treatment 1.Patient factors: Age, ECOG, toxicity from previous treatment and any comorbidity 2.Disease related factors: high risk cytogenetic ??, duration of response from previous treatments, cytogenetics data 3.Treatment related factors -Previous treatments -Duration of response -Previous toxicity? Patient related factors: renal insufficiency • Agents not requiring renal dose • Agents requiring renal dose adjustment adjustment • Lenalidomide • Bortezomib • CrCl 30-60 mL/min: 10 mg PO qDay; • Carfilzomib • CrCl <30 mL/min (not requiring dialysis): 15 mg PO every other day • If elevated serum creatinin not attributed to carfilzomib • CrCl <30 mL/min (requiring dialysis): 5 mg PO q Day; on dialysis days • Thalidomide • Ixazomib • Pomalidomide • Only in ESRD: reduced dose to 3 mg • Liposomal doxorubicin • Melphalan • Monoclonal Abs • CrCl 30-50 mL/min: 50% dose • Daratumumab reduction • Elotuzumab • Avoid if CrCl < 30 mL/min • Cyclophosphamide • CrCl < 10 mL/min: 50% dose reduction When use carfilzomib in renal insufficiency, serum creatinine should be closely monitored • 35% of patients had a reduction of eGFR >25% Nookaa,a et al.
Load more

Recommended publications
  • DF6079-TBRG4 Antibody
    Affinity Biosciences website:www.affbiotech.com order:[email protected] TBRG4 Antibody Cat.#: DF6079 Concn.: 1mg/ml Mol.Wt.: 71kDa Size: 100ul,200ul Source: Rabbit Clonality: Polyclonal Application: WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000 *The optimal dilutions should be determined by the end user. Reactivity: Human,Mouse,Rat Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific). Specificity: TBRG4 Antibody detects endogenous levels of total TBRG4. Immunogen: A synthesized peptide derived from human TBRG4, corresponding to a region within C-terminal amino acids. Uniprot: Q969Z0 Description: TBRG4 (transforming growth factor beta regulator 4), also known as CPR2 (cell cycle progression restoration protein 2) or FASTKD4 (FAST kinase domain-containing protein 4), is a 631 amino acid protein that contains one RAP domain and belongs to the FAST kinase family. TBRG4 is ubiquitously expressed and may have a role in cell cycle progression. Existing as two alternatively spliced isoforms, the gene encoding TBRG4 maps to human chromosome 7p13. Chromosome 7 is approximately 158 million bases long, encodes over 1000 genes and makes up about 5% of the human genome. Chromosome 7 has been linked to Osteogenesis imperfecta, Pendred syndrome, Lissencephaly, Citrullinemia and Shwachman-Diamond syndrome. The deletion of a portion of the q arm of chromosome 7 is associated with Williams-Beuren syndrome, a condition characterized by mild mental retardation, an unusual comfort and friendliness with strangers and an elfin appearance. Deletions of portions of the q arm of chromosome 7 are also seen in a number of myeloid disorders including cases of acute myelogenous leukemia and myelodysplasia.
    [Show full text]
  • Noelia Díaz Blanco
    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
    [Show full text]
  • Global Mapping of Herpesvirus-‐Host Protein Complexes Reveals a Novel Transcription
    Global mapping of herpesvirus-host protein complexes reveals a novel transcription strategy for late genes By Zoe Hartman Davis A dissertation submitted in partial satisfaction of the Requirements for the degree of Doctor of Philosophy in Infectious Disease and Immunity in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Britt A. Glaunsinger, Chair Professor Laurent Coscoy Professor Qiang Zhou Spring 2015 Abstract Global mapping of herpesvirus-host protein complexes reveals a novel transcription strategy for late genes By Zoe Hartman Davis Doctor of Philosophy in Infectious Diseases and Immunity University of California, Berkeley Professor Britt A. Glaunsinger, Chair Mapping host-pathogen interactions has proven instrumental for understanding how viruses manipulate host machinery and how numerous cellular processes are regulated. DNA viruses such as herpesviruses have relatively large coding capacity and thus can target an extensive network of cellular proteins. To identify the host proteins hijacked by this pathogen, we systematically affinity tagged and purified all 89 proteins of Kaposi’s sarcoma-associated herpesvirus (KSHV) from human cells. Mass spectrometry of this material identified over 500 high-confidence virus-host interactions. KSHV causes AIDS-associated cancers and its interaction network is enriched for proteins linked to cancer and overlaps with proteins that are also targeted by HIV-1. This work revealed many new interactions between viral and host proteins. I have focused on one interaction in particular, that of a previously uncharacterized KSHV protein, ORF24, with cellular RNA polymerase II (RNAP II). All DNA viruses encode a class of genes that are expressed only late in the infectious cycle, following replication of the viral genome.
    [Show full text]
  • Og Raunvísindasvið - Líftækni
    Háskólinn á Akureyri Viðskipta- og raunvísindasvið - Líftækni Námskeið LOK1126 og LOK1226 Heiti verkefnis Characterization of cathelicidin gene family members in Rock Ptarmigan (Lagopus muta) Verktími Janúar – maí 2017 Nemandi Hallgrímur Steinsson Leiðbeinandi Kristinn Pétur Magnússon Upplag Rafrænt auk þriggja prentaðra eintaka Blaðsíðufjöldi 53 Fjöldi viðauka 1 Fylgigögn Engin Útgáfu- og notkunarréttur Opið verkefni Yfirlýsingar „Ég lýsi því yfir að ég einn er höfundur þessa verkefnis og að það er afrakstur eigin rannsókna“ _________________________________ Hallgrímur Steinsson, 210878-5649 „Það staðfestist að verkefni þetta fullnægir að mínum dómi kröfum til prófs í námskeiðunum LOK1126 og LOK1226“ __________________________________ Kristinn P. Magnússon, leiðbeinandi ii Abstract Cathelicidins are a class of antimicrobial peptides expressed in vertebrate species which are part of the innate immune system. The aim of this thesis was to resolve genomic organization of the cathelicidin gene cluster in rock ptarmigan (Lagopus muta) and to predict the amino sequence of the mature peptides and analyze expression. To locate the cathelicidin genes the chicken (Gallus gallus) genome sequences were used to blast a novel draft genome of rock ptarmigan. The draft genome was subsequently used to design primers for PCR and sequencing, to enable obtaining the entire cathelicidin cluster. The characterization of the cathelicidin cluster in rock ptarmigan revealed all four cathelicidin genes orthologues found in chicken and turkey (Meleagris gallopavo), namely CATHL1, CATH2, CATH3, CATHB1, flanked by KLH18 and TBRG4, in the same order on chromosome 2. The genes map to a 15kb region, which is of similar size in chicken. The quality of the region is good except for two minor gaps of ~100bp.
    [Show full text]
  • Product Data Sheet
    For research purposes only, not for human use Product Data Sheet Anti-TBRG4 Antibody Catalog # Source Reactivity Applications CQA1006 Rabbit H, M, R WB, IF/IC Description Rabbit polyclonal antibody to TBRG4 Immunogen Recombinant full length protein of human TBRG4 Purification The antibody was purified by immunogen affinity chromatography. Specificity Recognizes endogenous levels of TBRG4 protein. Clonality Polyclonal Conjugation Form Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. Dilution WB (1/500 - 1/2000), IF/IC (1/50 - 1/200) Gene Symbol TBRG4 Alternative Names CPR2; FASTKD4; KIAA0948; Protein TBRG4; Cell cycle progression restoration protein 2; Cell cycle progression protein 2; FAST kinase domain-containing protein 4; Transforming growth factor beta regulator 4 Entrez Gene 9238 (Human); 21379 (Mouse); 360977 (Rat) SwissProt Q969Z0 (Human); Q91YM4 (Mouse); Q5M9G9 (Rat) Storage/Stability Shipped at 4°C. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles. Application key: E- ELISA, WB- Western blot, IH- Immunohistochemistry, IF- Immunofluorescence, FC- Flow cytometry, IC- Immunocytochemistry, IP- Immunoprecipitation, ChIP- Chromatin Immunoprecipitation, EMSA- Electrophoretic Mobility Shift Assay, BL- Blocking, SE- Sandwich ELISA, CBE- Cell-based ELISA, RNAi- RNA interference Species reactivity key: H- Human, M- Mouse, R- Rat, B- Bovine, C- Chicken, D- Dog, G- Goat, Mk- Monkey, P- Pig, Rb- Rabbit, S- Sheep, Z- Zebrafish COHESION BIOSCIENCES LIMITED WEB ORDER SUPPORT CUSTOM www.cohesionbio.com [email protected] [email protected] [email protected] For research purposes only, not for human use Product Data Sheet Western blot analysis of TBRG4 expression in Hela (A), HepG2 (B) whole cell lysates.
    [Show full text]
  • A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2018 A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family Linda Molla Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Linda Molla June 2018 © Copyright by Linda Molla 2018 A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY Linda Molla, Ph.D. The Rockefeller University 2018 APOBEC2 is a member of the AID/APOBEC cytidine deaminase family of proteins. Unlike most of AID/APOBEC, however, APOBEC2’s function remains elusive. Previous research has implicated APOBEC2 in diverse organisms and cellular processes such as muscle biology (in Mus musculus), regeneration (in Danio rerio), and development (in Xenopus laevis). APOBEC2 has also been implicated in cancer. However the enzymatic activity, substrate or physiological target(s) of APOBEC2 are unknown. For this thesis, I have combined Next Generation Sequencing (NGS) techniques with state-of-the-art molecular biology to determine the physiological targets of APOBEC2. Using a cell culture muscle differentiation system, and RNA sequencing (RNA-Seq) by polyA capture, I demonstrated that unlike the AID/APOBEC family member APOBEC1, APOBEC2 is not an RNA editor. Using the same system combined with enhanced Reduced Representation Bisulfite Sequencing (eRRBS) analyses I showed that, unlike the AID/APOBEC family member AID, APOBEC2 does not act as a 5-methyl-C deaminase.
    [Show full text]
  • A Mitochondria-Specific Isoform of FASTK Is Present In
    Article A Mitochondria-Specific Isoform of FASTK Is Present In Mitochondrial RNA Granules and Regulates Gene Expression and Function Graphical Abstract Authors Alexis A. Jourdain, Mirko Koppen, ..., Maria Simarro, Jean-Claude Martinou Correspondence [email protected] In Brief The mitochondrial genome is required for ATP production, but little is known about its expression. Jourdain et al. report that FASTK localizes to mitochondrial RNA granules and is essential for ND6 mRNA biogenesis and complex I activity via a mechanism of mRNA 30 end processing in human mitochondria. Highlights d A mitochondrial isoform of FASTK co-localizes with mitochondrial RNA granules d FASTK binds multiple sites along ND6 mRNA and its precursors d FASTK modulates degradosome activity to generate mature ND6 mRNA d ND6 mRNA levels and complex I activity are decreased in the absence of FASTK Jourdain et al., 2015, Cell Reports 10, 1110–1121 February 24, 2015 ª2015 The Authors http://dx.doi.org/10.1016/j.celrep.2015.01.063 Cell Reports Article A Mitochondria-Specific Isoform of FASTK Is Present In Mitochondrial RNA Granules and Regulates Gene Expression and Function Alexis A. Jourdain,1 Mirko Koppen,1,6 Christopher D. Rodley,1 Kinsey Maundrell,1 Naı¨gGueguen,2 Pascal Reynier,2 Adela M. Guaras,3 Jose´ A. Enriquez,3 Paul Anderson,4 Maria Simarro,4,5 and Jean-Claude Martinou1,* 1Department of Cell Biology, University of Geneva, 30 quai Ernest-Ansermet, 1211 Gene` ve 4, Switzerland 2UMR CNRS 6214 - INSERM 1083, De´ partement de Biochimie et Ge´ ne´ tique,
    [Show full text]
  • Renoprotective Effect of Combined Inhibition of Angiotensin-Converting Enzyme and Histone Deacetylase
    BASIC RESEARCH www.jasn.org Renoprotective Effect of Combined Inhibition of Angiotensin-Converting Enzyme and Histone Deacetylase † ‡ Yifei Zhong,* Edward Y. Chen, § Ruijie Liu,*¶ Peter Y. Chuang,* Sandeep K. Mallipattu,* ‡ ‡ † | ‡ Christopher M. Tan, § Neil R. Clark, § Yueyi Deng, Paul E. Klotman, Avi Ma’ayan, § and ‡ John Cijiang He* ¶ *Department of Medicine, Mount Sinai School of Medicine, New York, New York; †Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; ‡Department of Pharmacology and Systems Therapeutics and §Systems Biology Center New York, Mount Sinai School of Medicine, New York, New York; |Baylor College of Medicine, Houston, Texas; and ¶Renal Section, James J. Peters Veterans Affairs Medical Center, New York, New York ABSTRACT The Connectivity Map database contains microarray signatures of gene expression derived from approximately 6000 experiments that examined the effects of approximately 1300 single drugs on several human cancer cell lines. We used these data to prioritize pairs of drugs expected to reverse the changes in gene expression observed in the kidneys of a mouse model of HIV-associated nephropathy (Tg26 mice). We predicted that the combination of an angiotensin-converting enzyme (ACE) inhibitor and a histone deacetylase inhibitor would maximally reverse the disease-associated expression of genes in the kidneys of these mice. Testing the combination of these inhibitors in Tg26 mice revealed an additive renoprotective effect, as suggested by reduction of proteinuria, improvement of renal function, and attenuation of kidney injury. Furthermore, we observed the predicted treatment-associated changes in the expression of selected genes and pathway components. In summary, these data suggest that the combination of an ACE inhibitor and a histone deacetylase inhibitor could have therapeutic potential for various kidney diseases.
    [Show full text]
  • CREB-Dependent Transcription in Astrocytes: Signalling Pathways, Gene Profiles and Neuroprotective Role in Brain Injury
    CREB-dependent transcription in astrocytes: signalling pathways, gene profiles and neuroprotective role in brain injury. Tesis doctoral Luis Pardo Fernández Bellaterra, Septiembre 2015 Instituto de Neurociencias Departamento de Bioquímica i Biologia Molecular Unidad de Bioquímica y Biologia Molecular Facultad de Medicina CREB-dependent transcription in astrocytes: signalling pathways, gene profiles and neuroprotective role in brain injury. Memoria del trabajo experimental para optar al grado de doctor, correspondiente al Programa de Doctorado en Neurociencias del Instituto de Neurociencias de la Universidad Autónoma de Barcelona, llevado a cabo por Luis Pardo Fernández bajo la dirección de la Dra. Elena Galea Rodríguez de Velasco y la Dra. Roser Masgrau Juanola, en el Instituto de Neurociencias de la Universidad Autónoma de Barcelona. Doctorando Directoras de tesis Luis Pardo Fernández Dra. Elena Galea Dra. Roser Masgrau In memoriam María Dolores Álvarez Durán Abuela, eres la culpable de que haya decidido recorrer el camino de la ciencia. Que estas líneas ayuden a conservar tu recuerdo. A mis padres y hermanos, A Meri INDEX I Summary 1 II Introduction 3 1 Astrocytes: physiology and pathology 5 1.1 Anatomical organization 6 1.2 Origins and heterogeneity 6 1.3 Astrocyte functions 8 1.3.1 Developmental functions 8 1.3.2 Neurovascular functions 9 1.3.3 Metabolic support 11 1.3.4 Homeostatic functions 13 1.3.5 Antioxidant functions 15 1.3.6 Signalling functions 15 1.4 Astrocytes in brain pathology 20 1.5 Reactive astrogliosis 22 2 The transcription
    [Show full text]
  • Identification of Neoepitopes Recognized by Tumor-Infiltrating Lymphocytes (Tils) from Patients with Glioma
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 28), pp: 19469-19480 Research Paper: Immunology Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma Davide Valentini1, Martin Rao2, Qingda Meng2, Anna von Landenberg2, Jiri Bartek Jr3,4, Georges Sinclair4, Georgia Paraschoudi2, Elke Jäger5, Inti Harvey-Peredo4, Ernest Dodoo4 and Markus Maeurer1,2,5 1Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden 2Therapeutic Immunology Unit (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet, Stockholm, Sweden 3Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark 4Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden 5 Krankenhaus Nordwest, Division of Oncology and Hematology, Frankfurt, Germany Correspondence to: Markus Maeurer, email: [email protected] Keywords: tumor-infiltrating lymphocytes; immunotherapy; neoepitopes; glioblastoma; interferon gamma; Immunology Received: September 11, 2017 Accepted: February 24, 2018 Published: April 13, 2018 Copyright: Valentini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Neoepitope-specific T-cell responses have been shown to induce durable clinical responses in patients with advanced cancers. We explored the recognition patterns of tumor-infiltrating T lymphocytes (TILs) from patients with glioblastoma multiforme (GBM), the most fatal form of tumors of the central nervous system. Whole-genome sequencing was used for generating DNA sequences representing the entire spectrum of ‘private’ somatic mutations in GBM tumors from five patients, followed by 15-mer peptide prediction and subsequent peptide synthesis.
    [Show full text]
  • TBRG4 (NM 030900) Human Tagged ORF Clone – RC222933L4 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC222933L4 TBRG4 (NM_030900) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: TBRG4 (NM_030900) Human Tagged ORF Clone Tag: mGFP Symbol: TBRG4 Synonyms: CPR2; FASTKD4 Vector: pLenti-C-mGFP-P2A-Puro (PS100093) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC222933). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_030900 ORF Size: 1563 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 TBRG4 (NM_030900) Human Tagged ORF Clone – RC222933L4 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_030900.2 RefSeq Size: 1961 bp RefSeq ORF: 1566 bp Locus ID: 9238 UniProt ID: Q969Z0, Q969Z0-2 MW: 58.4 kDa Gene Summary: Plays a role in processing of mitochondrial RNA precursors and in stabilization of a subset of mature mitochondrial RNA species, such as MT-CO1, MT-CO2, MT-CYB, MT-CO3, MT-ND3, MT- ND5 and MT-ATP8/6.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]